Development of indazole Rho-kinase (ROCK 1) inhibitors as potential antihypertensive agents

被引：0

作者：

Goodman, Krista Beaver ^{[1
]}

Dowdell, Sarah E. ^{[1
]}

Gaitanopoulos, Dimitri E. ^{[1
]}

Ivy, Robert ^{[1
]}

Sehon, Clark ^{[1
]}

Stavenger, Robert ^{[1
]}

Wang, Gren ^{[1
]}

Viet, Andrew Q. ^{[1
]}

Xu, Weiwei ^{[1
]}

Ye, Guosen ^{[1
]}

Semus, Simon F. ^{[2
]}

Evans, Christopher

Fries, Harvey E. ^{[3
]}

Jolivette, Larry J. ^{[3
]}

Jung, David K. ^{[1
]}

Wright, Lois L. ^{[4
]}

Smith, Gary K. ^{[4
]}

Behm, David J. ^{[5
]}

Bentley, Ross ^{[5
]}

Doe, Christopher P. ^{[5
]}

Hu, Erding ^{[5
]}

Lee, Dennis ^{[1
]}

机构：

[1] GlaxoSmithKline Inc, Dept Med Chem, King Of Prussia, PA 19406 USA

[2] GlaxoSmithKline Inc, Dept Computat & Struct Sci, King Of Prussia, PA 19422 USA

[3] GlaxoSmithKline Inc, Dept Drug Metab & Pharmacokinet, King Of Prussia, PA 19406 USA

[4] GlaxoSmithKline Inc, Screening & Compound Profiling, King Of Prussia, PA 19406 USA

[5] GlaxoSmithKline Inc, Cardiovasc & Urogenital CEDD, Biol, King Of Prussia, PA 19406 USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2009年 / 238卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

252-MEDI

引用

页数：1

共 50 条

[21] Potent, Selective and Orally Bioavailable Dihydropyrimidine Inhibitors of Rho Kinase (ROCK1) as Potential Therapeutic Agents for Cardiovascular Diseases
Sehon, Clark A.
Wang, Gren Z.
Viet, Andrew Q.
Goodman, Krista B.
Dowdell, Sarah E.
Elkins, Patricia A.
Semus, Simon F.
Evans, Christopher
Jolivette, Larry J.
Kirkpatrick, Robert B.
Dul, Edward
Khandekar, Sanjay S.
Yi, Tracey
Wright, Lois L.
Srnith, Gary K.
Behm, David J.
Bentley, Ross
Doe, Christopher P.
Hu, Erding
Lee, Dennis
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (21) : 6631 - 6634
[22] Design and synthesis of novel indazole derivatives as Rho kinase inhibitors
Nishida, Hiroshi
Komori, Ken-ichi
Izumi, Naoyuki
Hagihara, Masahiko
Tsuzaki, Yasunori
Sunamoto, Hidetoshi
Yoshimura, Kimihiko
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
[23] Role of Rho-kinase and its inhibitors in pulmonary hypertension
Duong-Quy, Sy
Bei, Yihua
Liu, Zhongmin
Dinh-Xuan, Anh Tuan
PHARMACOLOGY & THERAPEUTICS, 2013, 137 (03) : 352 - 364
[24] Rho-kinase inhibitors show promise in pulmonary hypertension
Doggrell, SA
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (09) : 1157 - 1159
[25] Rho-Kinase Inhibitors as Emerging Targets for Glaucoma Therapy
Wang, Jun
Wang, Hanke
Dang, Yalong
OPHTHALMOLOGY AND THERAPY, 2023, 12 (06) : 2943 - 2957
[26] Rho-kinase inhibitors: Role in corneal endothelial disorders
Singh, Nimish Kumar
Sahu, Srikant Kumar
SEMINARS IN OPHTHALMOLOGY, 2023, 38 (01) : 9 - 14
[27] Rho-Kinase Inhibitors as Emerging Targets for Glaucoma Therapy
Jun Wang
Hanke Wang
Yalong Dang
Ophthalmology and Therapy, 2023, 12 (6) : 2943 - 2957
[28] Effect of the Rho-Kinase/ROCK Signaling Pathway on Cytoskeleton Components
Guan, Guangzhao
Cannon, Richard D. D.
Coates, Dawn E. E.
Mei, Li
GENES, 2023, 14 (02)
[29] Rho-Kinase/ROCK: A Key Regulator of the Cytoskeleton and Cell Polarity
Amano, Mutsuki
Nakayama, Masanori
Kaibuchi, Kozo
CYTOSKELETON, 2010, 67 (09) : 545 - 554
[30] Advances in the development of Rho-associated protein kinase (ROCK) inhibitors
Pan, Peichen
Shen, Mingyun
Yu, Huidong
Li, Youyong
Li, Dan
Hou, Tingjun
DRUG DISCOVERY TODAY, 2013, 18 (23-24) : 1323 - 1333

← 1 2 3 4 5 →